Recent Updates
Recently added Catalysts
CGON Positive Sentiment

SUO 2025 – CRETO-EAP TIPS EPOSTER

Key Takeaway: CG Oncology is set to present at the SUO 2025 conference, showcasing their ongoing commitment to advancing research in bladder cancer. The company has recently reported positive results from their CORE-1008 Phase 2 trial, which focuses on a combination therapy for high-risk patients. Additionally, they have announced award recipients for their Non-Muscle Invasive Bladder Cancer Research Fellowship.
Price reaction · baseline $44.84 (2025-11-28 close) · hit pre-market · clean, no other CGON news in the window
day 0 close · peak
-3.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • CG Oncology is actively participating in multiple conferences.
  • Positive results reported from CORE-1008 trial.
  • Recognition of research fellowship award recipients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+139%
120-day peak, hindsight
Typical move
6.3%
average across 5 past catalysts
Cash runway
~66 mo
Minimal dilution risk
Lead asset
CG0070
Phase 2 · Non Muscle Invasive Bladder Cancer

Full Press Release Details

by admin | Dec 1, 2025 | congress-hub-posters | 0 comments

Recent Posts

• CUA 2026 – BOND-003 Cohort C Podium
• CG Oncology to Present at Upcoming Investor Conferences in June
• SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
• CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
• AUA 2026 – CORE 008 Cohort CX Presentation

Recent Comments

Frequently Asked Questions

What is the focus of CG Oncology's presentation at SUO 2025?

CG Oncology will present their research and findings related to bladder cancer.

What recent trial results did CG Oncology report?

They reported positive results from the CORE-1008 Phase 2 trial.

What award was announced by CG Oncology?

They announced the recipients of the Non-Muscle Invasive Bladder Cancer Research Fellowship.

When is the SUO 2025 conference taking place?

The SUO 2025 conference is scheduled for December 1, 2025.

Last updated: Dec 1, 2025